Clearside Biomed Financials
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Clearside Biomed has an operating margin of -1735.7%, meaning the company retains $-1736 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is down from -302.0% the prior year.
Clearside Biomed's revenue declined 79.8% year-over-year, from $8.2M to $1.7M. This contraction results in a growth score of 0/100.
With a current ratio of 4.44, Clearside Biomed holds $4.44 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While Clearside Biomed generated -$24.7M in operating cash flow, capex of $977K consumed most of it, leaving -$25.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Clearside Biomed passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, Clearside Biomed generates $0.72 in operating cash flow (-$24.7M OCF vs -$34.4M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
This page shows Clearside Biomed (CLSD) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Key Financial Metrics
Clearside Biomed generated $1.7M in revenue in fiscal year 2024. This represents a decrease of 79.8% from the prior year.
Clearside Biomed's EBITDA was -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.6% from the prior year.
Clearside Biomed generated -$25.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 28.9% from the prior year.
Clearside Biomed reported -$34.4M in net income in fiscal year 2024. This represents a decrease of 5.7% from the prior year.
Clearside Biomed earned $-0.47 per diluted share (EPS) in fiscal year 2024. This represents an increase of 11.3% from the prior year.
Clearside Biomed held $20.0M in cash against $0 in long-term debt as of fiscal year 2024.
Clearside Biomed had 5M shares outstanding in fiscal year 2024. This represents a decrease of 91.9% from the prior year.
Clearside Biomed's gross margin was 91.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the prior year.
Clearside Biomed's operating margin was -1735.7% in fiscal year 2024, reflecting core business profitability. This is down 1433.7 percentage points from the prior year.
Clearside Biomed's net profit margin was -2064.4% in fiscal year 2024, showing the share of revenue converted to profit. This is down 1669.5 percentage points from the prior year.
Clearside Biomed invested $18.6M in research and development in fiscal year 2024. This represents a decrease of 10.8% from the prior year.
Clearside Biomed invested $977K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 45.0% from the prior year.
CLSD Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $201K-59.1% | $492K-78.9% | $2.3M+661.4% | $306K+240.0% | $90K-60.9% | $230K-96.4% | $6.3M+638.6% | $859K |
| Cost of Revenue | $0 | $0-100.0% | $248K+66.4% | $149K | $0 | $0 | N/A | $142K |
| Gross Profit | $201K-59.1% | $492K-76.4% | $2.1M+1226.1% | $157K+74.4% | $90K-60.9% | $230K | N/A | $717K |
| R&D Expenses | $2.9M+85.2% | $1.6M-64.5% | $4.5M+5.2% | $4.2M-7.8% | $4.6M-18.0% | $5.6M-11.1% | $6.3M+23.0% | $5.1M |
| SG&A Expenses | $4.3M+74.0% | $2.5M-12.3% | $2.8M-7.8% | $3.1M-0.5% | $3.1M+9.0% | $2.8M-4.2% | $2.9M+11.8% | $2.6M |
| Operating Income | -$7.0M-97.3% | -$3.6M+31.5% | -$5.2M+27.2% | -$7.1M+5.8% | -$7.6M+7.5% | -$8.2M-181.6% | -$2.9M+58.7% | -$7.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | $0 | $0-100.0% | $715K | $0 | $0 | $0 | N/A | N/A |
| Net Income | -$6.0M-32.9% | -$4.5M+45.3% | -$8.2M-12.6% | -$7.3M+3.8% | -$7.6M+35.4% | -$11.8M-143.4% | -$4.8M+47.9% | -$9.3M |
| EPS (Diluted) | $-1.14 | $-0.06+45.5% | $-0.11-108.2% | $1.34+1440.0% | $-0.10+41.2% | $-0.17-112.5% | $-0.08+46.7% | $-0.15 |
CLSD Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.6M-24.1% | $15.3M-22.0% | $19.7M-21.7% | $25.1M-26.0% | $33.9M-15.5% | $40.1M+18.0% | $34.0M-1.2% | $34.4M |
| Current Assets | $8.3M-30.0% | $11.8M-26.2% | $16.0M-25.0% | $21.3M-28.5% | $29.8M-17.6% | $36.1M+19.9% | $30.1M-2.2% | $30.8M |
| Cash & Equivalents | $6.8M-27.5% | $9.4M-31.2% | $13.6M-31.9% | $20.0M+9.8% | $18.2M-48.4% | $35.4M+22.3% | $28.9M+0.4% | $28.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | $266K-67.4% | $816K-46.9% | $1.5M+203.4% | $507K | $0 | $0-100.0% | $467K-47.1% | $882K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $65.6M+2.4% | $64.1M-2.3% | $65.6M+2.5% | $64.0M+2.8% | $62.2M+0.4% | $62.0M+24.1% | $49.9M+5.6% | $47.3M |
| Current Liabilities | $2.8M-9.1% | $3.0M-39.2% | $5.0M+4.5% | $4.8M-18.4% | $5.9M-1.3% | $6.0M-12.7% | $6.8M+16.8% | $5.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | -$54.0M-10.7% | -$48.7M-6.2% | -$45.9M-18.2% | -$38.9M-37.4% | -$28.3M-29.7% | -$21.8M-37.1% | -$15.9M-23.8% | -$12.8M |
| Retained Earnings | -$374.0M-1.6% | -$368.0M-1.2% | -$363.5M-2.3% | -$355.3M-4.4% | -$340.3M-2.3% | -$332.7M-3.7% | -$320.9M-1.5% | -$316.1M |
CLSD Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$5.5M-15.9% | -$4.7M+18.9% | -$5.8M-11.0% | -$5.3M+7.5% | -$5.7M+27.7% | -$7.9M-1686.1% | $495K+108.1% | -$6.1M |
| Capital Expenditures | $0 | $0-100.0% | $9K-98.0% | $444K+5.0% | $423K+642.1% | $57K-52.5% | $120K-73.0% | $445K |
| Free Cash Flow | -$5.5M-15.9% | -$4.7M+19.0% | -$5.8M-2.5% | -$5.7M+6.6% | -$6.1M+22.8% | -$7.9M-2208.8% | $375K+105.8% | -$6.5M |
| Investing Cash Flow | $0 | $0+100.0% | -$9K-100.1% | $9.3M+181.4% | -$11.4M-19964.9% | -$57K+52.5% | -$120K+73.0% | -$445K |
| Financing Cash Flow | $2.9M+509.0% | $477K+186.3% | -$553K-126.6% | $2.1M | $0-100.0% | $14.3M+5680.9% | -$257K-181.1% | $317K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CLSD Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0%0.0pp | 100.0%+10.6pp | 89.4%+38.0pp | 51.3%-48.7pp | 100.0%0.0pp | 100.0% | N/A | 83.5% |
| Operating Margin | -3502.5%-2777.3pp | -725.2%-501.8pp | -223.4%+2112.9pp | -2336.3%+6097.1pp | -8433.3%-4864.2pp | -3569.1%-3523.2pp | -45.9%+775.3pp | -821.2% |
| Net Margin | -2971.1%-2057.5pp | -913.6%-560.7pp | -352.9%+2034.7pp | -2387.6%+6051.3pp | -8438.9%-3324.5pp | -5114.4%-5038.2pp | -76.1%+1002.7pp | -1078.8% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -51.3%-22.0pp | -29.3%+12.5pp | -41.8%-12.7pp | -29.1%-6.7pp | -22.4%+6.9pp | -29.3%-15.1pp | -14.2%+12.7pp | -26.9% |
| Current Ratio | 2.98-0.9 | 3.87+0.7 | 3.19-1.3 | 4.44-0.6 | 5.07-1.0 | 6.07+1.6 | 4.42-0.9 | 5.28 |
| Debt-to-Equity | -1.22+0.1 | -1.31+0.1 | -1.43+0.2 | -1.65+0.6 | -2.20+0.6 | -2.84+0.3 | -3.14+0.5 | -3.68 |
| FCF Margin | -2726.4%-1765.2pp | -961.2%-710.6pp | -250.6%+1611.5pp | -1862.1%+4919.0pp | -6781.1%-3342.8pp | -3438.3%-3444.2pp | 5.9%+764.9pp | -759.0% |
Note: Shareholder equity is negative (-$38.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Frequently Asked Questions
What is Clearside Biomed's annual revenue?
Clearside Biomed (CLSD) reported $1.7M in total revenue for fiscal year 2024. This represents a -79.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clearside Biomed's revenue growing?
Clearside Biomed (CLSD) revenue declined by 79.8% year-over-year, from $8.2M to $1.7M in fiscal year 2024.
Is Clearside Biomed profitable?
No, Clearside Biomed (CLSD) reported a net income of -$34.4M in fiscal year 2024, with a net profit margin of -2064.4%.
What is Clearside Biomed's earnings per share (EPS)?
Clearside Biomed (CLSD) reported diluted earnings per share of $-0.47 for fiscal year 2024. This represents a 11.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Clearside Biomed's EBITDA?
Clearside Biomed (CLSD) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Clearside Biomed's gross margin?
Clearside Biomed (CLSD) had a gross margin of 91.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clearside Biomed's operating margin?
Clearside Biomed (CLSD) had an operating margin of -1735.7% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Clearside Biomed's net profit margin?
Clearside Biomed (CLSD) had a net profit margin of -2064.4% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Clearside Biomed's free cash flow?
Clearside Biomed (CLSD) generated -$25.7M in free cash flow during fiscal year 2024. This represents a -28.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clearside Biomed's operating cash flow?
Clearside Biomed (CLSD) generated -$24.7M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Clearside Biomed's total assets?
Clearside Biomed (CLSD) had $25.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Clearside Biomed's capital expenditures?
Clearside Biomed (CLSD) invested $977K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Clearside Biomed spend on research and development?
Clearside Biomed (CLSD) invested $18.6M in research and development during fiscal year 2024.
How many shares does Clearside Biomed have outstanding?
Clearside Biomed (CLSD) had 5M shares outstanding as of fiscal year 2024.
What is Clearside Biomed's current ratio?
Clearside Biomed (CLSD) had a current ratio of 4.44 as of fiscal year 2024, which is generally considered healthy.
What is Clearside Biomed's debt-to-equity ratio?
Clearside Biomed (CLSD) had a debt-to-equity ratio of -1.65 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Clearside Biomed's return on assets (ROA)?
Clearside Biomed (CLSD) had a return on assets of -136.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Clearside Biomed's cash runway?
Based on fiscal year 2024 data, Clearside Biomed (CLSD) had $20.0M in cash against an annual operating cash burn of $24.7M. This gives an estimated cash runway of approximately 10 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Clearside Biomed's debt-to-equity ratio negative or unusual?
Clearside Biomed (CLSD) has negative shareholder equity of -$38.9M as of fiscal year 2024, which causes the debt-to-equity ratio to appear negative or not meaningful. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Clearside Biomed's Piotroski F-Score?
Clearside Biomed (CLSD) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clearside Biomed's earnings high quality?
Clearside Biomed (CLSD) has an earnings quality ratio of 0.72x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Clearside Biomed?
Clearside Biomed (CLSD) scores 25 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.